MOPP
MOPP
MOPP (/mɒp/, an acronym for Mustargen, Oncovin, Procarbazine, and Prednisone) is a combination chemotherapy regimen used to treat Hodgkin's disease. The regimen was developed in the 1960s and was the first combination chemotherapy regimen that was able to cure advanced stage Hodgkin's disease.
Etymology
The term MOPP is an acronym derived from the names of the four drugs used in the regimen:
- Mustargen (also known as mechlorethamine)
- Oncovin (also known as vincristine)
- Procarbazine
- Prednisone
Usage
MOPP is used in the treatment of both early-stage and advanced-stage Hodgkin's disease. The regimen is typically administered in cycles, with each cycle lasting four weeks. Patients receive the Mustargen and Oncovin on the first and eighth days of the cycle, and the Procarbazine and Prednisone on the first through the fourteenth days of the cycle.
Side Effects
Like all chemotherapy regimens, MOPP has potential side effects. These can include nausea, vomiting, hair loss, and fatigue. More serious side effects can include infertility, lung damage, and an increased risk of secondary cancers, particularly leukemia.
Related Terms
- Chemotherapy: The use of drugs to treat cancer.
- Hodgkin's disease: A type of lymphoma, which is a cancer of the lymphatic system.
- Lymphoma: A group of blood cell tumors that develop from lymphocytes (a type of white blood cell).
- Mustargen: A chemotherapy drug used in the MOPP regimen.
- Oncovin: A chemotherapy drug used in the MOPP regimen.
- Procarbazine: A chemotherapy drug used in the MOPP regimen.
- Prednisone: A steroid drug used in the MOPP regimen.
External links
- Medical encyclopedia article on MOPP
- Wikipedia's article - MOPP
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski